x
09/2020 Ventures

OCCIDENT INVESTS IN DEEP TECH

As a deep tech investor, we are pleased to be perceived as such by the University of Zurich. OCCIDENT is one of the most active investors in life sciences spin-offs from Swiss universities, which account for almost one third of our portfolio. Together with our German spin-offs, almost two thirds of our start-ups’ technologies were developed at universities or research institutions. For us, this once again demonstrates the great potential of excellent research in Switzerland and Germany.

Read more

09/2020 Ventures

TOP 100 SWISS START-UP AWARD 2020

Just like in 2019, we congratulate three of our portfolio companies on their placements among this year’s TOP 100 Swiss Startup Award – two of them even made it into the TOP 8. Congratulations to Versantis, Resistell and hemotune for their ranking as 3 of the most promising startups in Switzerland. OCCIDENT is proud to have these aspiring startups in its portfolio.

More about Versantis

More about Resistell

More about hemotune

09/2020 GROUP

NEW ADDRESS IN MUNICH

Growth needs space that’s why we are moving with our Munich team into our own and bigger offices near the Gärtnerplatz. We are very much looking forward to welcoming our portfolio companies, further team members and business partners and to meeting highly motivated founders in the Isarvorstadt.

08/2020 Team

WELCOME SIMON

OCCIDENT welcomes Simon Schild von Spannenberg as new Junior Investment Manager for the high-tech sector at the Munich office. Simon studied Industrial Engineering (Mechanical Engineering) as well as Energy Science and Engineering at the Technical University of Darmstadt and spent a semester abroad in Nicaragua. Afterwards he gained experience as a founder and in the field of M&A with a focus on Cleantech. At OCCIDENT, Simon is responsible for deal sourcing and building a high-tech start-up portfolio.

08/2020 Ventures

INVESTMENT IN HEMOTUNE

For the third month in a row, we are proud to welcome a new venture to our portfolio. OCCIDENT acted as lead investor for the Series A of the Swiss start-up hemotune, which developed HemoSystem, a groundbreaking platform technology for extracorporeal blood purification. This technology uses magnetic nanoparticles to purify the blood of previously inaccessible pathogenic biomolecules and toxins. The primary applications are sepsis and septic shock, the consequences of which up to 6 million people die every year according to the WHO.

More information can be found in the press release under the following link.

More about hemotune

07/2020 Ventures

INVESTMENT IN TUBULIS

OCCIDENT participates in the Series A financing round of the Munich-based start-up Tubulis, which is working on one of the best current innovations for improved cancer treatment. Using proprietary platform technologies, Tubulis develops uniquely tailored Antibody Drug Conjugates (ADCs) with the aim of improving and expanding their therapeutic potential. The conjugates consist of chemotherapeutic agents that are firmly bound to a cancer-sensitive antibody which enables a specific release of the drug molecule at the tumor site. Tubulis is thus developing the basis for a more targeted and effective therapy of cancer.

More information can be found in the press release under the following link.

More about Tubulis

07/2020 Ventures

Resistell receives EIC Accelerator Grant

In times of COVID-19, the signs are more in favor of saving than investing. Especially life sciences start-ups can therefore only develop or test their life-saving technologies at a slower pace. This makes it all the more important for us to support young companies in the current situation. We are therefore very pleased that the European Commission has the same ambition and supports Resistell in the generation of an improved method for detecting antibiotic resistance with the Enhanced European Innovation Council (EIC) Accelerator Grant totaling 2.5 million euros.

More information can be found in the press release under the following link.

More about Resistell

06/2020 Ventures

INVESTMENT IN CODE INTELLIGENCE

OCCIDENT invests in the Bonn-based start-up Code Intelligence. Together with LBBW Venture Capital und investiere, a very good consortium has been formed for the Pre-Series A financing round. Code Intelligence enables software security testing through innovative fuzzing already in the development phase of software. Using CI Fuzz, vulnerabilities can be detected earlier and fully automatically, allowing developers to analyze errors faster and to fix them at the code base. Thus CI Fuzz drastically improves the stability and reliability of software.

More information can be found in the press release under the following link.

More about Code Intelligence

show more